Baxter’s Chinese API Supplier Cited For “Objectionable Practices;” Remaining Heparin Vials Recalled

U.S. FDA has issued a Form 483 to Changzhou SPL, Baxter Healthcare's heparin API supplier, after inspecting the Changzhou City plant, FDA announced Feb. 28 during an update of the agency's ongoing investigation of Baxter's heparin products